Drug-Induced Liver Injury Is a Major Risk for New Drugs

Digestive Diseases

Volumn 33, Issue 4, 2015, Pages 458-463

  Seeff, Leonard B ^a,b  

^a Einstein Healthcare Network   (United States)

^b NONE   (United States)

Author keywords

Causality assessment; Drug induced liver injury; e DISH; Food and Drug Administration; Hy's law

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; NEW DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHRONIC HEPATITIS C; DRUG APPROVAL; DRUG MONITORING; FOOD AND DRUG ADMINISTRATION; HEPATITIS C VIRUS; HUMAN; LIVER DYSFUNCTION; LIVER INJURY; LIVER TOXICITY; MEDICAL ASSESSMENT; PRIORITY JOURNAL; TOXIC HEPATITIS; UNITED STATES; BLOOD; DRUG SCREENING; DRUG-INDUCED LIVER INJURY; LIVER FUNCTION TEST; PROCEDURES;

ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASES; DRUG APPROVAL; DRUG EVALUATION; DRUG-INDUCED LIVER INJURY; HUMANS; LIVER FUNCTION TESTS; UNITED STATES;

EID: 84937418919     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000374089     Document Type: Article

References (16)

1. Regev A: Drug-induced liver injury and drug development: industry perspective. Semin Liver Dis 2014; 34: 227-239.
2. Senior JR: Evolution of the Food and Drug Administration to liver safety assessment for new drugs: current status and challenges. Drug Saf 2014; 37(suppl 1):S9-S17.
3. Zimmerman HJ: Hepatotoxicity: the Adverse Effects of Drugs and Other Chemicals on the Liver, ed 2. Philadelphia, Lipincott, Williams &Wilkins, 1999.
4. Prati D, Taioli E, Zanella A, Del Torre E, Butelli S, Del Vecchio E, Vianello L, et al: Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10.
5. Kariv R, Leshno M, Beth-Or A, Strul H, Blendis L, Kokia E, Noff D, et al: Re-evaluation of serum alanine aminotransferase upper normal limits and its modulating factors in large-scale population study. Liver Int 2006; 25: 445-460.
6. Lee JK, Shim JH, Lee HC, Lee SH, Kim KM, Lim YS, Chung YH, et al: Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology. Hepatology 2010; 51: 1577-1583.
7. Food and Drug Administration: Guidance for industry: premarketing risk assessment. 2005. Www.fda.gov/downloads/Drugs/Guidance/ UCM174090.pdf.
8. Aithal GP, Watkins PB, Andrade RJ, Larry D, MoloChalasani N, Davern T, Khia M, Takikawa H, Hunt CM, et al: Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011; 89: 806-815.
9. Pockros PJ: Drugs in development for chronic hepatitis C: a promising future. Expert Opin Biol Ther 2011; 11: 1611-1622.
10. Kohli A, Shaffer A, Sherman A, Kottihli S: Treatment of hepatitis C: a systematic review. JAMA 2014; 312: 631-640.
11. Temple R: Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 2006; 5: 241-243.
12. Danan G, Benichou C: Causality assessment of adverse reactions to drugs. I. A novel model based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-1330.
13. Benichou C, Danan G, Flahault A: Causality assessment of adverse reactions to drugs. II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993; 46: 1331-1336.
14. Lee WM: Drug-induced acute liver failure. Clin Liv Dis 2013; 17: 575-586.
15. Benichou C: Criteria of drug-induced liver disorders: report of an international consensus meeting. J Hepatol 1990; 11: 272-276.
16. Food and Drug Administration: Medical product safety information. Http://www.fda. Gov/medwatch/safety.htm.